Phenicia Group

Phenicia is a clinical-stage biotechnology company focused on developing innovative therapies for metabolic and inflammatory diseases, with a primary emphasis on metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. The company's lead programs target key metabolic pathways, including the farnesoid X receptor (FXR) and thyroid hormone receptor beta (THR-beta), to address the underlying drivers of liver fibrosis and metabolic dysfunction. Phenicia aims to provide effective treatment options for patients with chronic liver conditions through precision-targeted small molecule candidates. Led by experienced industry veterans, the company leverages deep expertise in drug development to advance its pipeline through clinical validation.